Latest Headlines

1. Cambrex To Acquire Snapdragon Chemistry, A Leader In Continuous Flow API Development Services 11/21/2022

   Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.

2. Caribou Biosciences Announces FDA Clearance Of IND Application For CB-011, An Allogeneic Anti-BCMA CAR-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma 11/21/2022

   Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-011, a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking.

3. Prepaire Announces Partnership With Ncardia To Accelerate Plans To Discover New Drugs & Repurpose Existing Libraries 11/21/2022

   Prepaire Labs, an Omics company, mining, mapping & navigating biology and chemistry to empower their autonomous drug discovery and production operating system (OS), and Ncardia, the leader in developing stem cell-based solutions for drug discovery and cell therapy, today announced the signing of a 5-year agreement.

4. Nona Biosciences Enters Into HCAb Based Drug Discovery Collaboration Agreement With Dragonfly Therapeutics 11/21/2022

   Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona's proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.

5. Cleveland Researchers Discover New Oral Drug For Lowering Cholesterol 11/18/2022

   After statins, the next leading class of medications for managing cholesterol are PCSK9 inhibitors. These highly effective agents help the body pull excess cholesterol from the blood, but unlike statins, which are available as oral agents, PCSK9 inhibitors can only be administered as shots, creating barriers to their use.

6. ACROBiosystems Launches A New Logistics Center In Switzerland To Help Accelerate Drug Development Throughout Europe 11/18/2022

   ACROBiosystems Group has announced the launch of its first European logistics center and warehouse in Basel, Switzerland. This marks the first step towards ACROBiosystems' commitment to globalization by providing swift deliveries to their pharmaceutical partners in Europe.

7. A Path To Faster And More Cost-Effective Drug Development 11/18/2022

   Researchers at Rensselaer Polytechnic Institute (RPI) have published research in Molecular Pharmaceuticals predicting how proteins interact in drug development. The research, funded by the National Science Foundation (NSF), is in collaboration with Amgen and University of Michigan – Ann Arbor. In the paper, researchers use a mathematical model to predict the viscosity of solutions of proteins to be used as drugs.

8. Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation For Avacincaptad Pegol For Geographic Atrophy 11/17/2022

   IVERIC bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).

9. Rezo, Founded By Renowned UCSF Scientists, Launches With $78M Series A To Advance Pipeline Of Precision Therapeutics Based On Groundbreaking Integrated Disease Network Mapping Platform 11/17/2022

   Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing.

10. MilliporeSigma Invests $ 286M In U.S. Drug Safety Testing Capacity 11/16/2022

    MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA.